Balance Sheet: Liabilities and Stockholders’ Equity

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Abbott Laboratories, consolidated balance sheet: liabilities and stockholders’ equity

US$ in millions

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Short-term borrowings	—)	—)	—)	—)	213)
Trade accounts payable	4,195)	4,295)	4,607)	4,408)	3,946)
Salaries, wages and commissions	1,701)	1,597)	1,556)	1,625)	1,416)
Accrued rebates payable to government agencies	621)	650)	638)	364)	316)
Accrued other rebates	1,098)	1,091)	1,087)	1,082)	805)
All other	3,424)	3,681)	4,120)	3,735)	4,044)
Other accrued liabilities	5,143)	5,422)	5,845)	5,181)	5,165)
Dividends payable	1,024)	955)	887)	831)	798)
Income taxes payable	594)	492)	343)	306)	362)
Current portion of long-term debt	1,500)	1,080)	2,251)	754)	7)
Current liabilities	14,157)	13,841)	15,489)	13,105)	11,907)
Long-term debt, excluding current portion	12,625)	13,599)	14,522)	17,296)	18,527)
Defined benefit pension plans and post-employment medical and dental plans for significant plans	1,880)	1,964)	1,784)	2,738)	3,119)
Deferred income taxes	512)	568)	991)	1,392)	1,406)
Operating lease liability, non-current	896)	949)	943)	956)	902)
All other	3,443)	3,466)	3,804)	3,685)	3,684)
Post-employment obligations and other long-term liabilities	6,731)	6,947)	7,522)	8,771)	9,111)
Long-term liabilities	19,356)	20,546)	22,044)	26,067)	27,638)
Total liabilities	33,513)	34,387)	37,533)	39,172)	39,545)
Preferred shares, one dollar par value, none issued	—)	—)	—)	—)	—)
Common shares, without par value	25,153)	24,869)	24,709)	24,470)	24,145)
Common shares held in treasury, at cost	(16,844)	(15,981)	(15,229)	(11,822)	(10,042)
Earnings employed in the business	47,261)	37,554)	35,257)	31,528)	27,627)
Accumulated other comprehensive loss	(7,906)	(7,839)	(8,051)	(8,374)	(8,946)
Total Abbott shareholders’ investment	47,664)	38,603)	36,686)	35,802)	32,784)
Noncontrolling interests in subsidiaries	237)	224)	219)	222)	219)
Total shareholders’ investment	47,901)	38,827)	36,905)	36,024)	33,003)
Total liabilities and shareholders’ investment	81,414)	73,214)	74,438)	75,196)	72,548)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Download chart

Balance sheet item	Description	The company
Current liabilities	Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.	Abbott Laboratories current liabilities decreased from 2022 to 2023 but then slightly increased from 2023 to 2024.
Long-term liabilities	Amount of obligation due after one year or beyond the normal operating cycle, if longer.	Abbott Laboratories long-term liabilities decreased from 2022 to 2023 and from 2023 to 2024.
Total liabilities	Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.	Abbott Laboratories total liabilities decreased from 2022 to 2023 and from 2023 to 2024.
Total Abbott shareholders’ investment	Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.	Abbott Laboratories total Abbott shareholders’ investment increased from 2022 to 2023 and from 2023 to 2024.

Abbott Laboratories (NYSE:ABT)

Balance Sheet: Liabilities and Stockholders’ Equity